Bank of America’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-37,513
| Closed | -$69.4K | – | 8158 |
|
|
2023
Q1 | $69.4K | Sell |
37,513
-3,239,186
| -99% | -$4.01M | ﹤0.01% | 6389 |
|
|
2022
Q4 | $3.64M | Buy |
3,276,699
+3,265,185
| +28,358% | +$4.65M | ﹤0.01% | 3706 |
|
|
2022
Q3 | $27K | Buy |
11,514
+2,718
| +31% | +$9.63K | ﹤0.01% | 6930 |
|
|
2022
Q2 | $27K | Sell |
8,796
-39,303
| -82% | -$191K | ﹤0.01% | 7091 |
|
|
2022
Q1 | $327K | Sell |
48,099
-13,193
| -22% | -$94K | ﹤0.01% | 6123 |
|
|
2021
Q4 | $512K | Buy |
61,292
+51,989
| +559% | +$428K | ﹤0.01% | 5834 |
|
|
2021
Q3 | $69K | Sell |
9,303
-3,919
| -30% | -$24.3K | ﹤0.01% | 6900 |
|
|
2021
Q2 | $90K | Sell |
13,222
-16,939
| -56% | -$141K | ﹤0.01% | 6571 |
|
|
2021
Q1 | $310K | Buy |
30,161
+24,146
| +401% | +$264K | ﹤0.01% | 5725 |
|
|
2020
Q4 | $42K | Sell |
6,015
-2,569
| -30% | -$20K | ﹤0.01% | 6387 |
|
|
2020
Q3 | $70K | Sell |
8,584
-2,170
| -20% | -$13.5K | ﹤0.01% | 5861 |
|
|
2020
Q2 | $74K | Sell |
10,754
-1,052
| -9% | -$5.67K | ﹤0.01% | 5813 |
|
|
2020
Q1 | $56K | Buy |
11,806
+4,073
| +53% | +$23.4K | ﹤0.01% | 5826 |
|
|
2019
Q4 | $68K | Sell |
7,733
-26,396
| -77% | -$143K | ﹤0.01% | 6158 |
|
|
2019
Q3 | $113K | Sell |
34,129
-5,113
| -13% | -$20.5K | ﹤0.01% | 5989 |
|
|
2019
Q2 | $194K | Buy |
39,242
+8,134
| +26% | +$43.2K | ﹤0.01% | 5654 |
|
|
2019
Q1 | $193K | Sell |
31,108
-3,974
| -11% | -$19.2K | ﹤0.01% | 5541 |
|
|
2018
Q4 | $118K | Buy |
35,082
+9,544
| +37% | +$44.6K | ﹤0.01% | 5820 |
|
|
2018
Q3 | $166K | Sell |
25,538
-3,069
| -11% | -$22.8K | ﹤0.01% | 5592 |
|
|
2018
Q2 | $219K | Buy |
28,607
+20,276
| +243% | +$292K | ﹤0.01% | 5361 |
|
|
2018
Q1 | $187K | Buy |
8,331
+573
| +7% | +$12.7K | ﹤0.01% | 5410 |
|
|
2017
Q4 | $99K | Buy |
7,758
+4,358
| +128% | +$64.1K | ﹤0.01% | 5743 |
|
|
2017
Q3 | $53K | Buy |
3,400
+1,208
| +55% | +$17.1K | ﹤0.01% | 5920 |
|
|
2017
Q2 | $30K | Buy |
2,192
+1,030
| +89% | +$22K | ﹤0.01% | 6090 |
|
|
2017
Q1 | $26K | Buy |
+1,162
| New | +$24.6K | ﹤0.01% | 6210 |
|
Other funds holding JNCE
Bank of America's JNCE Position: Q2 2023 in Review
Bank of America sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 37,513 shares — an estimated $69.4K sold.
Bank of America first reported a position in JNCE in Q1 2017 and held it in 25 quarters. The position peaked at $3.64M in Q4 2022. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Bank of America reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Bank of America sold 37,513 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $69.4K.
- Bank of America first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 25 quarters.
- Bank of America's Jounce Therapeutics, Inc. Common Stock position peaked at $3.64M in Q4 2022.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Bank of America's 13F filing for Q2 2023, filed 14 Aug 2023.